AVITA Medical, Inc.RCELEarnings & Financial Report
Avita Medical is a clinical and commercial company developing and marketing a range regenerative medicine products. The first regenerative medicine product brought to the market by Avita Medical was ReCell spray-on skin for the treatment of burns. The two latest products are ReNovaCell, for Aesthetics and Plastic applications including skin trauma, and ReGenerCell for the treatment of chronic wounds. The Avita Medical regenerative product range is currently marketed in Europe, the Middle East...
Revenue
$18.5M
Gross Profit
$15.7M
Operating Profit
$-11.8M
Net Profit
$-13.9M
Gross Margin
84.7%
Operating Margin
-63.9%
Net Margin
-74.9%
YoY Growth
66.7%
EPS
$-0.53
Financial Flow
AVITA Medical, Inc. Q1 2025 Financial Summary
AVITA Medical, Inc. reported revenue of $18.5M (up 66.7% YoY) for Q1 2025, with a net profit of $-13.9M (up 25.7% YoY) (-74.9% margin). Cost of goods sold was $2.8M, operating expenses totaled $27.5M.
Key Financial Metrics
| Total Revenue | $18.5M |
|---|---|
| Net Profit | $-13.9M |
| Gross Margin | 84.7% |
| Operating Margin | -63.9% |
| Report Period | Q1 2025 |
AVITA Medical, Inc. Annual Revenue by Year
AVITA Medical, Inc. annual revenue history includes year-by-year totals (for example, 2025 revenue was $71.6M).
| Year | Annual Revenue |
|---|---|
| 2025 | $71.6M |
| 2024 | $64.3M |
| 2023 | $50.1M |
| 2022 | $34.4M |
AVITA Medical, Inc. Quarterly Revenue & Net Profit History
AVITA Medical, Inc. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 2025 | $17.6M | -4.3% | $-11.6M | -66.0% |
| Q3 2025 | $17.1M | -12.7% | $-13.2M | -77.3% |
| Q2 2025 | $18.4M | +21.2% | $-9.9M | -53.9% |
| Q1 2025 | $18.5M | +66.7% | $-13.9M | -74.9% |
| Q4 2024 | $18.4M | +29.7% | $-11.6M | -63.0% |
| Q3 2024 | $19.5M | +43.2% | $-16.2M | -82.9% |
| Q2 2024 | $15.2M | +29.3% | $-15.4M | -101.3% |
| Q1 2024 | $11.1M | +5.3% | $-18.7M | -168.0% |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $11.1M | $15.2M | $19.5M | $18.4M | $18.5M | $18.4M | $17.1M | $17.6M |
| YoY Growth | 5.3% | 29.3% | 43.2% | 29.7% | 66.7% | 21.2% | -12.7% | -4.3% |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $97.4M | $87.8M | $81.1M | $79.7M | $69.6M | $58.1M | $63.7M | $56.4M |
| Liabilities | $64.0M | $63.5M | $68.6M | $75.0M | $74.1M | $71.0M | $70.4M | $73.0M |
| Equity | $32.6M | $23.9M | $12.2M | $4.5M | $-4.6M | $-12.9M | $-6.7M | $-16.6M |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-20.9M | $-12.8M | $-7.2M | $-8.1M | $-10.3M | $-10.2M | $-5.2M | $-5.4M |